(Q46595019)

English

A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis

scientific article published on 16 March 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/26982815

A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/26982815

amyotrophic lateral sclerosis

0 references

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26982815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Ammar Al-Chalabi

1 reference

ORCID Public Data File 2021

author name string

Jeremy M Shefner

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26982815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Andrew A Wolff

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26982815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Lisa Meng

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26982815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Amy Bian

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26982815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Jacqueline Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26982815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Donna Barragan

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26982815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

BENEFIT-ALS Study Group

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26982815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

16 March 2016

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/26982815

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26982815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26982815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

5-6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26982815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

426-435

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26982815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

Tirasemtiv amplifies skeletal muscle response to nerve activation in humans

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

Phase II/III randomized trial of TCH346 in patients with ALS

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

Functional outcome measures as clinical trial endpoints in ALS.

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2016.1148169

21 January 2018

Identifiers

10.3109/21678421.2016.1148169

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26982815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26982815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46595019&oldid=2121264077"